<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1117</number>
    <updateDate>2025-11-19T05:00:38Z</updateDate>
    <updateDateIncludingText>2025-11-19T05:00:38Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <originChamberCode>H</originChamberCode>
    <type>HR</type>
    <introducedDate>2025-02-07</introducedDate>
    <congress>119</congress>
    <legislationUrl>https://www.congress.gov/bill/119th-congress/house-bill/1117</legislationUrl>
    <cdata>
      <constitutionalAuthorityStatementText>&lt;pre&gt;[Congressional Record Volume 171, Number 26 (Friday, February 7, 2025)][House]From the Congressional Record Online through the Government Publishing Office [&lt;a href="https://www.gpo.gov"&gt;www.gpo.gov&lt;/a&gt;]By Ms. DeLAURO:H.R. 1117.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clauses 3 and 18 of the United StatesConstitution.[Page H585]&lt;/pre&gt;</constitutionalAuthorityStatementText>
    </cdata>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred To</name>
            <date>2025-02-07T14:03:05Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Responsibility in Drug Advertising Act of 2025</title>
        <congress>119</congress>
        <number>483</number>
        <type>S</type>
        <latestAction>
          <actionDate>2025-02-06</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2025-02-07</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2025-02-07</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2025-02-07</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>D000216</bioguideId>
        <fullName>Rep. DeLauro, Rosa L. [D-CT-3]</fullName>
        <firstName>Rosa</firstName>
        <lastName>DeLauro</lastName>
        <party>D</party>
        <state>CT</state>
        <middleName>L.</middleName>
        <district>3</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Broadcasting, cable, digital technologies</name>
          <updateDate>2025-04-24T16:09:39Z</updateDate>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
          <updateDate>2025-04-24T16:09:39Z</updateDate>
        </item>
        <item>
          <name>Internet, web applications, social media</name>
          <updateDate>2025-04-24T16:09:39Z</updateDate>
        </item>
        <item>
          <name>Marketing and advertising</name>
          <updateDate>2025-04-24T16:09:39Z</updateDate>
        </item>
        <item>
          <name>Prescription drugs</name>
          <updateDate>2025-04-24T16:09:39Z</updateDate>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
        <updateDate>2025-03-11T18:02:05Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2025-02-07</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2025-07-23T18:45:01Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;strong&gt;Responsibility in Drug Advertising Act of 2025&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media.&amp;nbsp;&lt;/p&gt;&lt;p&gt;Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources.&amp;nbsp;&lt;/p&gt;&lt;p&gt;The prohibition applies to new drugs approved beginning one year before the bill’s enactment.&lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>Responsibility in Drug Advertising Act of 2025</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>Responsibility in Drug Advertising Act of 2025</title>
        <updateDate>2025-03-10T12:23:20Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Responsibility in Drug Advertising Act of 2025</title>
        <updateDate>2025-03-10T12:23:19Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.</title>
        <updateDate>2025-03-10T12:18:33Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2025-02-07T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-119hr1117ih/xml/BILLS-119hr1117ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2025-02-07</actionDate>
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
